Adherence to emicizumab prophylaxisin patients with haemophilia A:results of the first single-centre study in Russia

Abstract

Summary. Introduction. Treatment adherence is a key factor for clinical outcomes in patients with haemophilia A.Traditional factor replacement therapy is associated with a high treatment burden, which may affect adherence and overall quality of life. Emicizumab has the
potential to improve adherence through more effective haemostatic control combined with a less frequent dosing. Aim: to assess the emicizumab impact on treatment adherence in patients with haemophilia A and to identify key factors influencing adherence. Materials and
Methods. Between December 2023 and March 2024, a survey was conducted among 84 patients with haemophilia A residing in the NorthWestern Federal District of Russia. A specially designed questionnaire included items on treatment adherence, reasons for adherence, bleeding
frequency, and quality of life. Results. Adherence was reported at 100.0% among children and 97.8% among adults. The main reasons cited
for high adherence included reduced anxiety related to potential bleeding (82.9% in children, 75.7% in adults), ease of administration (91.5%
in children, 78.4% in adults), decreased injection frequency (87.2% in children, 83.8% in adults), and reduced pain during injection (76.6% in
children, 56.8% in adults). Parents of children statistically more often reported the absence of anxiety about venous access as a significant factor promoting adherence. Conclusion. Emicizumab ensures high treatment adherence in patients with haemophilia A across age groups
by alleviating anxiety about potential bleeding and reducing treatment burden.

For citation: Andreeva T.A., ZalepukhinaO.E., KonstantinovaV.N., Lavrechenko I.N., Leperova M.S., Nikolaeva N.N., Kuchin A.A., Arkhangelskaya N.A.
Adherence to emicizumab prophylaxis in patients with haemophilia A: results of the first single-centre study in Russia. Tromboz, gemostaz i reologiya.
2025;(3):21–27. (In Russ.).

References

1. Thornburg C.D., Duncan N.A. Treatment adherence in hemophilia.
Patient Prefer Adherence. 2017;11:1677–86. DOI: 10.2147/PPA.S139851.

2. Krishnan S., Vietri J., Furlan R., Duncan N. Adherence to prophylaxis
is associated with better outcomes in moderate and severe haemophilia: results of a patient survey. Haemophilia. 2015;21(1):64–70. DOI: 10.1111/hae.12533.

3. Brand B., Dunn S., Kulkarni R. Challenges in the management of
haemophilia on transition from adolescence to adulthood. Eur J
Haematol. 2015;95 Suppl 81:30–5. DOI: 10.1111/ejh.12582.

4. Witkop M.L., Mc Laughlin J.M., Anderson T.L. et al. Predictors of
non-adherence to prescribed prophylactic clotting-factor treatment regimens among adolescent and young adults with a bleeding disorder. Haemophilia. 2016;22(4): e245‑e250. DOI: 10.1111/hae.12951.

5. Fischer K., van der Bom J.G., Prejs R. et al. Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on
outcome. Haemophilia. 2001;7(6):544–50. DOI: 10.1046/j.1365‑251
6.2001.00560.x.

6. Schrijvers L.H., Kars M.C., Beijlevelt-van der Zande M. et al. Unravelling adherence to prophylaxis in haemophilia: a patients’ perspective. Haemophilia. 2015;21(5):612–21. DOI: 10.1111/hae.12660.

7. Tran D.Q., Barry V., Antun A. et al. Physician trust and depression influence adherence to factor replacement: a single-centre
cross-sectional study. Haemophilia. 2017;23(1):98–104. DOI: 10.1111/
hae.13078.

8. Walsh C.E., Valentino L.A. Factor VIII prophylaxis for adult patients
with severe haemophilia A: results of a US survey of attitudes and
practices. Haemophilia. 2009;15(5):1014–21. DOI: 10.1111/j.1365‑25
16.2009.02036.x.

9. Saxena K. Barriers and perceived limitations to early treatment of
hemophilia. J Blood Med. 2013;4:49–56. DOI: 10.2147/JBM.S43734.

10. Hemlibra (emicizumab). State Register of Medicines of the Russian Federation. Ministry of Health of the Russian Federation. Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid = 97c92f29–648a‑4b04–8cc2–41f59bc43a85. [Accessed: 01.06.2025].

11. Emicizumab. Summary of Product Characteristics for healthcare professionals [Regulatory document]. Registration number
ЛП-№ (001088)-(РГ-RU). The Ministry of Health of the Russian
Federation. 19.06.2025. (In Russ.).

12. Rumyantsev A.G. Hemophilia A  therapy in the 21st century:
a review of modern approaches and their effectiveness. Pediatriya
segodnya. 2024;(2):4–5. (In Russ.).

13. Basaric D., Saracevic M., Bosnic V. et al. Factor VIII activity in
relation to the type of thrombosis and patient’s risk factors for
thrombosis, age, and comorbidity. Eurasian J Med. 2023;55(1):9.
DOI: 10.5152/eurasianjmed.2023.22072.

14. Bearden D.J., Feinstein A., Cohen L.L. The Influence of parent
preprocedural anxiety on child procedural pain: mediation by child procedural anxiety. J Pediatr Psychol. 2012;37(6):680–6.
DOI: 10.1093/jpepsy/jss041.

15. Mahajerin A., Khairnar R., Meyer C.S. et al. Real-world persistence with and adherence to emicizumab prophylaxis in persons with hemophilia a: a secondary claims database analysis. Blood. 2020;136:13. DOI: 10.1182/blood‑2020‑137632.

16. Shapiro A.D., Schuldt R., Xia Z. et al. Real-world adherence and
persistence to emicizumab using a National US Claims Database.
Blood. 2024;144:3699. DOI: 10.1182/blood‑2024‑199645.

17. Li A., Goodfriend, C., Sokol J., Kruse-Jarres R. Patterns and predictors of emicizumab adherence in people with hemophilia. Blood.
2019;134:2178. DOI: 10.1182/blood‑2019‑128083.

18. Ettingshausen C.E., Eberl W., Eichler H. et al. Efficacy of emicizumab in patients with severe haemophilia A without factor VIII inhibitors in Germany: evaluation of real-life data documented by the smart medication eDiary. Ther Adv Hematol. 2024;15:20406207241295653. DOI: 10.1177/20406207241295653